Search Results 91-100 of 15757 for alt

1. A Multicenter Open Label Trial Using Ambrisentan in Patients with Porto-pulmonary Hypertension - Mayo Clinic

   Moribund state or anticipated death within 1 month. AST or ALT ≥ 5 times upper limit of normal; Total bilirubin ≥ 3.0 mg/dl; Significant lung disease ...

2. A Study of How Common Bile Acid Malabsorption is in Patients with Diarrhea Predominant Irritable Bowel Syndrome - Mayo Clinic

   If there are no AST or ALT values in the medical record, the study physicians will determine if the tests need to be run. Participating Mayo Clinic locations.

3. Accelerated Vs Standard BEP Chemotherapy For Patients With Intermediate And Poor-risk Metastatic Germ Cell Tumours - Mayo Clinic

   ... ALT and AST must be ≤2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be ≤ 5 x ULN 8. Adequate renal ...

4. A Study to Evaluate the Effectiveness and Safety of Remdesivir to Treat Coronavirus Disease 2019 in an Outpatient Setting - Mayo Clinic

   ALT or AST ≥ 5 × upper limit of normal ... Note: if per local practice only ALT is routinely measured, exclusion criteria will be evaluated on ALT alone.

5. Pemigatinib to Treat Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ... ALT (≤ 2.5 x ULN) = ______; ULN = ______. Serum phosphate < institutional ...

6. Study Of RSIFN-co For Patients With Advanced Solid Tumors - Mayo Clinic

   ... ALT > 1 x ULN, and HBV DNA >2000 IU/ml), or hepatitis C (defined as ALT > 1 x ULN, persistent viremia on antiviral therapy) infections; Has a history of ...

7. A Study To Evaluate Pembrolizumab And Dasatinib, Imatinib Mesylate, Or Nilotinib In Treating Patients With Chronic Myeloid Leukemia And Persistently- Detectable Minimal Residual Disease - Mayo Clinic

   AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases. ALT: ______ Institutional ULN: ______ Date of Test: ______; AST ...

8. Publications - Trevor J. Simard, M.D., Ph.D. - Mayo Clinic

   The ALT FLOW early feasibility study 3-year results assessing left atrial to coronary sinus shunting in HFpEF. ESC Heart Fail. 2026 Mar 3; 13 (2) View ...

9. Randomized Global Phase 3 Study to Evaluate the Impact of Obeticholic Acid Treatment on Nonalcoholic Steatohepatitis Patients - Mayo Clinic

   ALT >1.5 × upper limit of normal (ULN). For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E ...

10. Tucatinib And Trastuzumab For Patients With HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

    Total bilirubin ≤ 1.5 x upper limit of normal (ULN). Patients with known history of Gilbert Syndrome and total bilirubin < 3 x ULN and normal AST/ALT are ...